High Prevalence of Cancer and R&D in Anti-Cd39 Antibodies to Augment Growth of Anti-body Coupled T Receptor Therapy Market

 


Antibody-Coupled T cell Receptor (ACTR) is an autologous engineered T cell therapy that combines the Fc receptor, CD16, with endogenous T cell signaling and costimulatory domains. It is combined with tumor-targeting antibodies to exert potent anti-tumor immune responses and eliminate cancerous cells. ACRT has demonstrated potential in the treatment of multiple myeloma and HER2+ advanced cancers.

Market Dynamics

R&D in anti-CD39 antibodies is expected to propel growth of the Anti-body Coupled T Receptor Therapy Market. For instance, in December 2020, Arcus Biosciences, Inc. expanded its existing partnership with WuXi Biologics, a developer of biologics technology platforms, for R&D in anti-CD39 antibodies using WuXi Bio’s proprietary technology. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Increasing investment in R&D is expected to offer lucrative growth opportunities for players in the Anti-body Coupled T Receptor Therapy Market. For instance, in February 2021, Arcus Biosciences, Inc. received US$ 220 million to support and accelerate the company’s clinical development plans from Gilead Sciences, Inc., a U.S-based biopharmaceutical company, as the later increased its ownership in Arcus to 19.5%. Moreover, increasing number of clinical trials in antibody-coupled T receptor therapy is also expected to aid in growth of the market. For instance, in January 2020, Unum Therapeutics Inc. completed Cohort 1 enrollment with no dose-limiting toxiticies observed in the ATTCK-34-01 Phase 1 trial evaluating the company’s ACTR707, an antibody-coupled T cell receptor investigational therapy, together with trastuzumab for the treatment of patients with HER2+ advanced cancers.

The Anti-body Coupled T Receptor Therapy Market is witnessing several M&A activities. For instance, in July 2020, Cogent Biosciences (Unum Therapeutics) acquired Kiq LLC, a privately held, biotechnology company.

 Competitive Analysis

Major players operating in the Anti-body Coupled T Receptor Therapy Market include, Cogent Biosciences (Unum Therapeutics), Arcus Biosciences, Inc., and Seattle Genetics, Inc.

Major players operating in the Anti-body Coupled T Receptor Therapy Market are focused on R&D to expand their product portfolio. For instance, in 2018, Cogent Biosciences (Unum Therapeutics) received the U.S. patent design and use of the chimeric Antibody-Coupled T-cell Receptor (ACTR) platform technology for the  treatment of non-Hodgkin lymphoma, multiple myeloma, and HER2+ advanced cancers.


Comments

Post a Comment

Popular posts from this blog

Increasing Consumption and Production of Fertilizers to Upsurge the Growth of the Agrochemicals Market

Image
  Agrochemical products are those chemicals that are used to increase the production of an agricultural environment. Agrochemical chemicals typically include pesticides, fertilizers, lime precursors, acidizing and alkalizing agents (all of which are designed to alter the normal pH level of the soil), lime stabilizers, and other nutrients that are required for plant growth. These chemicals are widely used by farmers and are crucial to the functioning of modern agriculture. The use of these chemicals presents a number of concerns both from the perspective of the environment and the human body. The increasing need for improving crop production due to the growing concern of food security and lack of arable land is fueling the growth of agrochemicals market . Growing advancement in technology is raising adoption of advanced and sustainable farming practices which is again propelling the growth of the market. The increasing population coupled with the growing usage of fertilizers around th
Read more

Increasing Prevalence of Muscular Dystrophy to Augment the Muscular Dystrophy Treatment Market Growth

Image
  Muscular dystrophy is a common disease that causes muscles to become weaker and unable to continue to develop properly. Because it often affects young children as well as adults, it can be difficult to detect. However, once symptoms are noticed, steps must be taken to prevent the disease. There are many treatment options available for muscular dystrophy. The severity of the disease will determine what type of treatment is best for your situation. Muscular dystrophy treatment involves breathing aids, therapy, surgery, or medication, which may help maintain function, but life span is often shortened. Market Dynamics: Increasing prevalence or incidence of muscular dystrophy, especially in the North America, is expected to propel the growth of the muscular dystrophy treatment market . For instance, one in 3,500 male babies born worldwide are affected with Duchenne muscular dystrophy (DMD), according to the National Organization for Rare Disorders. Moreover, in 2019, around 349 new ca
Read more